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Abstract
Next-generation sequencing platforms are routinely used for molecular assignment due to their high impact for risk
stratification and prognosis in medulloblastomas. Yet, low and middle-income countries still lack an accurate cost-
effective platform to perform this allocation. TaqMan Low Density array (TLDA) assay was performed using a set of
20 genes in 92 medulloblastoma samples. The same methodology was assessed in silico using microarray data for
763 medulloblastoma samples from the GSE85217 study, which performed MB classification by a robust integrative
method (Transcriptional, Methylation and cytogenetic profile). Furthermore, we validated in 11 MBs samples our
proposed method by Methylation Array 450 K to assess methylation profile along with 390 MB samples (GSE109381)
and copy number variations. TLDA with only 20 genes accurately assigned MB samples into WNT, SHH, Group 3
and Group 4 using Pearson distance with the average-linkage algorithm and showed concordance with molecular
assignment provided by Methylation Array 450 k. Similarly, we tested this simplified set of gene signatures in 763
MB samples and we were able to recapitulate molecular assignment with an accuracy of 99.1% (SHH), 94.29%
(WNT), 92.36% (Group 3) and 95.40% (Group 4), against 97.31, 97.14, 88.89 and 97.24% (respectively) with the
Ward.D2 algorithm. t-SNE analysis revealed a high level of concordance (k = 4) with minor overlapping features
between Group 3 and Group 4. Finally, we condensed the number of genes to 6 without significantly losing
accuracy in classifying samples into SHH, WNT and non-SHH/non-WNT subgroups. Additionally, we found a
relatively high frequency of WNT subgroup in our cohort, which requires further epidemiological studies. TLDA is
a rapid, simple and cost-effective assay for classifying MB in low/middle income countries. A simplified method
using six genes and restricting the final stratification into SHH, WNT and non-SHH/non-WNT appears to be a very
interesting approach for rapid clinical decision-making.
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Introduction
Medulloblastoma (MB) is the most common malignant
brain tumor of children and adolescents, representing
20% of all pediatric brain tumors and is considered to be a
complex disease from a genetic perspective [31]. Current
consensus divides MB into four main molecular sub-
groups: SHH, WNT, Group 3 and Group 4. These sub-
groups have distinct transcriptional profiles, copy-number
aberrations, somatic mutations and clinical outcomes [2,
18, 22–24].
The molecular subgroups of MB have been incorporated
into risk stratification along with conventional biomarkers
and preclinical models to evaluate novel targeted inhibi-
tors and to substantiate further clinical trials [21, 23, 31].
The updated World Health Organization (WHO) classifi-
cation of the central nervous system (CNS) acknowledges
some of these molecular features as risk-stratification fac-
tors for MB [17]. Still, low and even middle-income coun-
tries cannot afford to routinely use these next-generation
sequencing (NSG) platforms for MB molecular subgroup-
ing. High costs related to these new technologies (e.g Illu-
mina Methylation array 450 k and NanoString nCounter®)
preclude their routine clinical application in most
low-income Nations.
As an initial attempt to equate this subject, Kunder
and colleagues [15] described a miRNA-based real-time
PCR assay platform that performed subgroup assign-
ment using a reduced set of 21 probes. However, ana-
lyses of Group 3 and Group 4MB subgroups were not
precisely discriminative when this approach was used
and no algorithm accuracy was validated for their
method. Similarly, Kaur and colleagues [12] published a
simplified approach based on immunohistochemistry
(IHC) and real time PCR (qPCR) methods for MB sub-
group allocation [12]. However, overlapping IHC stain-
ing was observed between subgroups. More recently,
complete datasets from cohort studies have become
publicly available, allowing the validation for new mo-
lecular classification and comparing novel stratification
proposals for gold standard NGS data. Accordingly, the
validation of new algorithms seems to be critical consid-
ering their increasing genomic and molecular import-
ance for therapeutic decisions [4, 7, 10, 16].
Here, we describe a low-cost and straightforward
method for molecular allocation of MB patients. We hy-
pothesized that a combination of qPCR with precise al-
gorithms would be a useful, simple and potent tool for
molecular assignment of MB tumors. We have opti-
mized the number of genes to molecularly classify pa-
tients into four and three groups of interest for clinical
management. We also present an elucidative algorithm
for MB subgroup assignment, validating our approach
and comparing our findings to data from 763MB sam-
ples molecularly assigned through a robust integrative
methodology (transcriptional, methylation and cytogen-
etic profiles) (GSE85217), as well as confirming our sub-
group findings by Methylation array in a sample subset.
Methods
Study group
Ninety-two patients diagnosed with MB and treated at
three Brazilian institutes were evaluated: 28 patients
from the University Hospital, Ribeirão Preto Medical
School, University of São Paulo (HC/FMRP-USP), 38
from The Boldrini Center of Children in Campinas São
Paulo State, and 26 from the Medical School of São
Paulo, University of São Paulo. In summary, 92
fresh-frozen MB tissue samples were microdissected by
a single pathologist (F.S.P) in the Pathology Department
(FMRP-USP). During microdissection, necrotic and nor-
mal tissues were removed from viable tumor areas. Pa-
tient age ranged from 1 to 24 years (median age = 7
years). Age groups at tumor diagnosis (clinical data from
88MB patients out of 92 cases were available) were: in-
fants (1–35months) 11/88, children (36 months - 8
years) 38/88, and adolescents (9 to 17 years) 35/88. Tu-
mors of young adults (age equals or above 18 + years) rep-
resented 4/88 of the case series. There was a slight male
preponderance, with a male to female ratio of 1.30:1.0.
From 92 samples, follow-up data of 80 patients were avail-
able and ranged from 1 to 168months, with a median ob-
servation period of 41months. Thirty-nine patients died
because of the disease (DOD), 37 patients showed no evi-
dence of disease (NED) at their last follow-up, and 4 pa-
tients (4.81%) died due to other unrelated events.
Follow-up from a period of 1 to 5 years was available for
73% (59/80) of patients and 30% (24/80) were followed for
more than 5 years. Two patients who lacked clinical infor-
mation (named as “na” from HC-FMP/USP) were in-
cluded in the heatmap for molecular assignment and were
not considered for further analysis (clinical, demographic
and survival (Additional file 1)). Patients’ clinical informa-
tion, outcome, demographic and information on Methyla-
tion profile are presented in Fig. 1.
TaqMan low density array (TLDA)
Microdissected fresh frozen tumor tissues were sub-
mitted to RNA extraction using the RNAeasy kit
(Qiagen). cDNA was synthetized in duplicate in a
25 μl reaction volume using 500 ng RNA from the
High Capacity Kit (Thermo). After RT-PCR, 25 μl of
DEPC water and 50 μl of Universal Master Mix (Life
Technologies) were added at a ratio of 1:1. The
TLDA plate layout was 31 + 1. The plate layout
manufacturing control used was GAPDH and 18S and
the reference genes used were TBP, HPRT and GUS-B.
Genes used for molecular assignment was retrieved
from Codeset described by Northcott and colleagues
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[18] and probe set and manufacturer’s code TaqMan
probe are listed in (Additional file 2: Table S1). Four
samples per plate were analyzed by conventional
Real-Time PCR, with 1 μl Reaction Predesigned added
to each well on Quant Studio 12 K flex (Thermo).
The relative quantification (RQ) of each protein-
coding gene compared with TBP, HPRT and GUS-B
was determined by the comparative cycle threshold
(Ct) method, where RQ 1/4 22(Ct Gene 2Ct
Ref ) × 100.
Molecular assignment of MB samples
Codeset genes expression analysis was used to generate a
pairwise distance matrix. Additionally, MB cell lines
a
b
c d e
Fig. 1 a Clinical characteristics of MB patients (n = 90). Classification Molecular classification: WNT subgroup, SHH subgroup, Group 3 and Group 4
of patients. Gender (female and male). Age at diagnosis (below or above 3 years). Metastasis presence of metastasis at diagnosis (yes, no); Relapse
presence of postoperative disease relapse (yes, no). Tumor resection (gross-total resection GTR; non-gross total resection non-GTR). Treatment treatment
protocol (craniospinal radiotherapy plus carboplatin, ifosfamide, vincristine, etoposide; craniospinal radiotherapy plus CCNU (1-(2-chloroethyl)-3-cyclohexyl-
1-nitrosourea), cisplatin, vincristine; Baby POG – Pediatric Oncology Group). Death if patient died (yes, no). Institution institute where patients received
treatment, Monosomy of chromosome 6 if patient bears this feature (yes, no), GLI2 Amplification if patients bears feature (yes, no), Isochromosome (17q)
if patient bears feature (yes, no), Methylation Array 450 K Molecular assignment by methylation array of WNT (6), SHH (2), Group 3 (2) and Group 4 (1)
samples. b Hierarchical unsupervised clustering of 92 primary MB into four molecular subgroups: SHH (green), WNT (purple), Group 3 (red) and Group 4
(blue). Pearson distance as Metric and average linkage as algorithm clustering. L1, L2, L3, L4 and L5 are represented as UW473, DAOY, UW402, UW228 and
ONS-76MB cell lines and “na” as samples tumors with unavailable data. c Copy number profile of sample 4 WNT subgroup (monosomy 6) (d) Copy
number profile of sample 26 SHH Subgroup (Amplification of GLI2) (e) Copy number profile of sample 55 Group 3 (Isochromosome 17q)
Cruzeiro et al. Acta Neuropathologica Communications            (2019) 7:33 Page 3 of 10
previously assigned to the SHH subgroup: DAOY,
UW228, ONS-76 [9, 18, 29, 30] and the UW402 and
UW473 (no subgroup information) were included in the
analysis.
For molecular subgroup assignment, unsupervised
hierarchical clustering was performed by Pearson dis-
tance correlation followed by an average-linkage algo-
rithm. Delta Ct values were used during analysis and a
Heatmap was generated using the Expression Suite® soft-
ware (Life Technologies). A total of 763MB samples
from the study of Cavalli and colleagues [1] (GSE85217)
in the R environment were analyzed for algorithm valid-
ation and heatmap comparison.
Molecular assignment of MB samples by methylation
array and copy number profiling
In order to assess concordance between TLDA assay and
the gold standard Illumina 450 K Methylation array, DNA
was extracted from 11 fresh frozen MB tumors and 250
ng were processed for genome-wide DNA methylation
analysis using the Illumina HumanMethylation450 Bead-
Chip (450 k). t-SNE analysis (t-Distributed Stochastic
Neighbor Embedding, Rtsne package version 0.11) was
performed and MB samples were randomly tested along
with 390MB reference samples molecularly assigned in
Capper and colleagues study (GSE109381) [1]. MB sam-
ples were further submitted to DNA methylation class
prediction and calibrated random forest class prediction
scores were generated using classifier version 11. b4 based
on the analysis of 10,000 CpG sites present in the 450 k.
For molecular subgrouping based on methylation class, an
optimal calibrated score threshold was defined as ≥0.5 for
a sufficient prediction as long as all family member scores
add up to a total score of ≥0.9. Additionally, copy-number
variations (CNV) analysis was performed using the ‘conu-
mee’ R package in bioconductor. Briefly, all CpGs are rep-
resented by a methylation probe and unmethylated probe.
For CNVs identification, the methylated and unmethylated
signal intensities are added together and a ratio is formed
against a healthy reference (e.g normal cerebellum tissue)
that bears a flat genome. Finally, the relative copy-number
is plotted in the corresponding area of chromosomal loca-
tion. The automatic score is verified by manual curation
of the respective loci for each individual profile [8, 29].
Bioinformatic analysis
The R language and environment for statistical computing
and graphics was used for bioinformatic analysis. The
ComplexHeatmap and circlize packages were used for
Heatmap generation [5, 6] and the ggplot2package [26,
32] was used for graphics generation. Rtsne [14, 10] was
used for the visualization of t-Distributed Stochastic
Neighbor Embedding (t-SNE) and the NbClust and Fac-
toextra packages [3, 11] were used to point out the best
number of clusters and to visualize the results. Pearson
correlation was used as a distance parameter and we se-
lected the clustering algorithms Ward.D2 or Average link-
age. To perform t-SNE, a method for constructing a low
dimensional embedding of high-dimensional data, dis-
tances or similarities, we used the default parameters, set-
ting only the perplexity parameter at 30, with 5–50 being
the typical and recommended range for robust analysis.
We then used NbClust with default parameters to find the
best number of cluster and to visualize the results.
Statistical analysis
The SPSS version 20 software (SPSS Inc., Chicago, IL,
USA) was used for statistical analysis. Descriptive statistics
and frequency distributions were calculated for all vari-
ables; the chi-square test and Fisher’s exact test were ap-
plied to explore association between variables. Patients’
event-free survival (EFS) rates were evaluated by
Kaplan-Meier curves and the log-rank test, considering re-
lapse/death as the event. P-values < 0.05 were considered
to be significant. [* < 0.05, ** < 0.01, *** < 0.001].
Results
TLDA accurately assigned most of the MB samples as WNT,
SHH, Group 3 and Group 4
As previously described [13, 15, 19] the SHH MB sub-
group was defined according to the expression of
PDLIM3, EYA1, HHIP, ATOH1, SFRP1, with EYA1 HHIP
and SFRP1 being the genes most expressed in 27 SHH
MB patients (30%). The WNT subgroup in 24 patients
(27%) was represented by the OAS1, WIFI1, DKK2, TNC,
GAD1 and EMX2 genes, withWIFI1, DKK2 and EMX2 be-
ing the most expressed genes in this subgroup. IMPG2,
EYS, NRL, GABRA5 expression was used to assign 11MB
samples (12%) to Group 3, and GABRA5 and NPR3 ex-
pression was the most specific subgroup compared to
Group 4. Twenty-eight Group 4 MBs (31%) were assigned
using KCNA1, EOMES, UNC5D, and RBM24 expression,
with KCNA1 and RBM24 being the most specific subgroup
compared to Group 3. Specifically,TNC showed higher ex-
pression in WNT subgroup and average expression in
SHH MB. The EYS gene was differentially expressed in
Group 3 and Group 4 (Fig. 1b). DAOY, UW228 and
ONS-76 cell lines were confirmed to belong to SHH sub-
group. UW473 and UW402 were subgrouped as SHH
MB as well.
Methylation and copy number profiling of MBs using
illumina methylation array 450 K showed high
concordance with TLDA
In order to validate our method, DNA available of 11
randomized MB patients were submitted to Methylation
array 450 K (Copy number profile available in Fig. 1).
We found a high concordance between Methylation
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array 450 K and TLDA for molecular assignment of
MBs. The t-SNE analysis of eleven MB samples along
with 390MB samples (GSE109381) showed high con-
cordance with TLDA method, being all samples assigned
in the same molecular subgroup (Additional file 3:
Figure S1). The DNA methylation class prediction and
calibrated random forest class prediction scores identi-
fied 6 WNT MBs, 2 SHH MBs, two Group 3 MBs and
one Group 4MB (Additional file 4: Table S2).
Additionally, copy number profiling identified mono-
somy in chromosome 6 in WNT subgroup (n = 5), GLI2
amplification in SHH (n = 1) and I (17q) for Group 3
MBs (n = 1) (Fig. 1c, d and e respectively).
T-SNE analysis revealed concordance between the Brazilian
cohort and the validation cohort and highlighted
overlapping features of group 3 and group 4
t-SNE analysis was performed to visualize clustering fea-
tures of molecular subgroups in perplexity index of 30.
We found four subgroups in the Brazilian cohort study,
with Group 3 and Group 4 bearing overlapping features
(k = 4). To validate this analysis, the t-SNE algorithm was
also applied to the validation cohort of 763MB samples
and the data obtained showed the same behavior (k = 4)
(Fig. 2a and b).
Average linkage and Ward.D2 are robust algorithms for
subgroup assignment of MB
In order to compare the clusterization feature algo-
rithms Ward and Average-linkage we applied our TLDA
approach to a validation cohort of 763 pre-classified MB
samples submitted to an integrative methodology com-
posed of transcriptional, methylation profile and cyto-
genetic features. Interestingly, we found both
Average-linkage and Ward.D2 to be feasible algorithms
for MB subgroup assignment using transcriptional data
alone. The Average-linkage algorithm successfully
assigned 221 of 223 SHH MB samples (99.10% accur-
acy), 66 from 70 WNT MB samples (94.29% of accur-
acy), 133 from 144MB Group 3MB samples (92.36%
accuracy), and 311 from 326 Group 4MB samples
(95.40% accuracy). Equally, the Ward.D2 algorithm suc-
cessfully assigned 216 of 223 SHH MB samples (97.31%
accuracy), 68 from 70 WNT MB samples (97.14% accur-
acy), 128 from 144MB Group 3MB samples (88.89% ac-
curacy), and 317 from 326 Group 4MB samples (97.24%
accuracy). (Fig. 3a and b) (Table 1).
Fig. 2 a Two-dimensional representation of pairwise sample correlations of twenty TaqMan expression assay probes (Additional file: Table S1) in
92 MB Brazilian samples by t-Distributed Stochastic Neighbor Embedding. b Two-dimensional representation of pairwise sample correlation of the
same gene set represented in (a) using Microarray probes in 763 MB samples from GSE85217 by t-Distributed Stochastic Neighbor Embedding
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Analysis of SFRP1, HHIP, EYA1, WIFI1, EMX2 and DKK2
expression potentially discriminated between SHH, WNT
from non-SHH/non-WNT MB
We further performed expression analysis of six key
genes that bear a positive signature for SHH (SFRP1,
HHIP, EYA1) and WNT (WIFI1, EMX2 and DKK2)
using Pearson as distance measurement and Ward.D2 or
Average linkage as clustering algorithms. We found that
the first cluster was characterized by a differential ex-
pression of SFRP1, HHIP and EYA1, which represent the
SHH subgroup. Another cluster that differentially car-
ried expression of WIFI1, EMX2 and DKK2 represented
the WNT subgroup. The third cluster, which carried
very low levels or lacked expression of the six genes, was
assigned as N-WNT/N-SHH. Similarly, in the validation
cohort of 763 samples, we identified the same behavior,
indicating the presence of three main clusters (Fig. 4a
and b). Using t-SNE analysis, we observed the same
consistent assignment of MB samples to 3 main clus-
ters (k = 3), with a minor overlap of clusters N-SHH/
N-WNT and SHH (Fig. 5a and b) (Additional file 5:
Figure S2a and b). The accuracy of subgroup
assignment using the set of six genes is showed in
Table 2a and b.
Discussion
In the present study, differential expression analysis of 20
genes from the CodeSet described by Northcott and col-
leagues [19] by TDLA approach permitted us to molecu-
larly assign a cohort of 92MB patients to the four major
MB subgroups. Additionally, we validated the same gene
set in a cohort of 763MB patients from the GSE85217
reference study, which applied the integrative-clustering
method to molecularly classify MB samples. The WNT
and SHH subgroups were robustly identified since they
formed a solid and concise cluster generated by the
Average-linkage or Ward.D2 algorithms and confirmed by
t-SNE analysis. In agreement, similar patterns were de-
tected using GSE85217 data analysis. We demonstrated
that assessment of the transcription profile is not suffi-
cient to completely discriminate all Group 3MB from
Group 4MB since a minority of these patients share tran-
scription and common molecular features [10, 12, 15, 18].
Next, in order to exam the concordance of our TDLA
approach with NGS subgrouping for MB we validated
molecular assignment of 11 MBs samples by Methyla-
tion Array 450 K. We found a high frequency of mono-
somy in chromosome 6 within WNT (5 out of 6)
subgroup corroborating with previous studies [2, 8, 13,
Fig. 3 Hierarchical unsupervised clustering of previously classified 763 primary MB in GSE85217 study: SHH (blue), WNT (orange), Group 3 (red)
and Group 4 (purple) Pearson distance as Metric was utilized in both heatmaps. a Clustering using the Ward.D2 algorithm. b Clustering using the
Average linkage algorithm
Table 1 Comparison of algorithm accuracy in the GSE85217 study (n = 763). Misassignment is defined as patients who were
incorrectly subgrouped
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28]. In one SHH MB samples evaluated by Methylation
array we identified GLI2 amplification. For Group 3, one
MB specimen bears isochromosome 17q, a reliable
marker for this subgroup [28] (Fig. 2B). Only one sample
for group 4 was identified, and it also clustered to group
4 by TLDA method accordingly. Full concordance be-
tween eleven MB samples by NGS and TDLA was
observed. Despite only a small set of samples was
assessed, the results from NGS data support our mo-
lecular assignment provided by TLDA [2, 8, 13, 28].
In the present study, we found 27% of WNT MBs
(Additional file 6: Figure S3a-S3d and Additional file 7:
Figure S4). Although this is a high frequency when com-
pared to studies performed in North American and
Fig. 4 Hierarchical unsupervised clustering using HHIP, EYA1, SFRP1, EMX2, DKK2, WIFI1 a 92 MB samples from Brazilian cohort and b 763 MB
samples from GSE85217. SHH (blue), WNT (orange), Group 3 (red) and Group 4 (purple)
Fig. 5 a Two-dimensional representation of pairwise sample correlations of 6 TaqMan expression assay probes (SFRP1, HHIP, EYA1, WIFI1, EMX2
and DKK2) in 92 MB Brazilian samples by t-Distributed Stochastic Neighbor Embedding. b Two- dimensional representation of pairwise sample
correlation of the same gene set represented in (a), although using Microarray probes of 763 MB samples from GSE85217 by t-Distributed
Stochastic Neighbor Embedding
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European continents [19], Kunder and colleagues [15]
reported 24% of WNT MBs in an Indian cohort. More-
over, pediatric neoplasms subtypes vary in frequency de-
pending on the genetic population background (i.e: high
frequency of Promyelocitic Leukemia in Latin America)
[20, 25]. Interestingly, we found 2 cases of desmoplastic
and 1 LCA in WNT MBs. Besides it is unlikely to find
desmosplastic histological variants in WNT MBs, our
data are supported by other studies [27]. In summary,
these epidemiological facts highlight the urge for a reli-
able, feasible and low-cost method to perform molecular
assignment of MBs in low and middle-income countries.
The average-linkage and Ward.D2 algorithms were
assessed regarding their clustering features and subgroup
assignment. In the GSE85217 study conducted on 763MB
patients, average-linkage provided better accuracy for SHH
and Group 3 assignment compared to the Ward.D2
method. However, Ward.D2 was able to accurately classify
WNT and Group 4 tumors. Interestingly, the pick of an ac-
curate clustering algorithm may be subgroup specific. How-
ever, it is very important to understand the limitations of
transcriptional data and information that can be extracted
from a single feature such as gene expression [2, 27, 33].
Indeed, as reported by Cavalli and colleagues [2], the gold
standard method for subgroup assignment is the assess-
ment of the molecular features of the patient (transcription
profile, methylation profile, cytogenetic profile) along with
clinical information. However, in low-income countries,
most molecular techniques are onerous for application to
daily clinical practice. Using expression analysis of a gene
set, algorithm assessment and bioinformatic analysis, we
sought to identify the minimal number of genes needed to
molecularly classify MB as WNT, SHH and non-SHH
/non-WNT. In our study, by using a set of six differentially
expressed genes we were able to distinguish SHH and
WNT from non-WNT/non-SHH without s significant loss
of accuracy. Both the Average-linkage and Ward.D2 algo-
rithms conserved 100% accuracy for assignment to the
WNT subgroup, with a decline to 85.18% for the SHH sub-
group. As shown in the t-SNE map, there was a minor
overlapping of samples of the non-SHH/non-WNT cluster
with those of the SHH cluster. Additionally, we found high
concordance between our data set and GSE85217, with
100% accuracy for the WNT subgroup and 86% accuracy
for SHH. These results shed new light on a potential
method for low-income countries based on a simple and
feasible technique such as qPCR along with six probe/pri-
mer pairs plus reference genes with implementation of an
approach recently described by Gómes and colleagues [3].
Their method fully discriminates between Group 3 and
Group 4 based on the methylation status of 5 CpG’s, which
is feasible for the real-time PCR platform through High
Resolution Melting technology, and shall improve the mo-
lecular assignment [26].
Northcott et al. described a molecular classification
method for MB that relies on the NanoString nCounter
System. Besides the high accuracy of the method (~ 98%),
the average cost is estimated at 60.00 USD per sample and
the method takes 3–4 days to perform bioinformatic ana-
lysis [19]. The same method was reproduced by Leal and
colleagues [16]; however, due to the high cost of the equip-
ment (287,817.60 USD – average price in South America;
2018), it is challenging for most low-income countries to
apply this method to clinical routine. Kaur et al. proposed
a minimal panel comprising a combination of IHC anti-
bodies and FISH probes to classify MB, with an estimate
cost around 150.00 to 250.00 USD (average) per sample
[12]. Although feasible, their approach does not seem to be
as cost-effective as other methods and IHC analysis re-
mains challenging due to different antibody batches and
inter-observer consistency [19]. More recently, the minimal
methylation classifier (MIMIC) was described as a highly
efficient methodology that might be superior to Illumina
450 K and Methylation EPIC array for MB molecular as-
signment regarding feasibility for clinical routines; however,
the average cost per sample with this approach is around
200.00 USD [26] and requires the acquisition of a MALDI-
TOF mass-spectrometer (approximately 150,000.00 USD),
along with a conventional PCR device. Our method using
TLDA has an estimated cost of 70.00 USD per sample (in-
cluding reagents, primers and laboratory implements). The
equipment necessary to run TLDA costs about 92,600.00
USD and complete data analysis is ready within one work-
ing day. Moreover, when we condensed the number of
studied genes to six (a set of TaqMan probes for: SFRP1,
HHIP, EYA1,WIFI1, EMX2 and DKK2 along with reference
genes HPRT and Gus-ß), the cost of molecular assignment
to the WNT, SHH and N-SHH/N-WNT MB subgroups
dropped to 26.82 USD per sample. Also, the real time-PCR
(30,000.00 USD) platform is relatively inexpensive and
commonly available in most hospitals due to its ample use
for other routine laboratory applications. Finally, another
Table 2 Comparison of algorithm accuracy using 6 genes to
assign WNT and SHH alone. (a) Study GSE85217 (n = 293). (b)
Brazilian cohort (n = 51). Misassignment is defined as patients
who were incorrectly subgrouped
Misassignment Accuracy
Subgroups Average-linkage Ward.D2 Average-linkage Ward.D2 
SHH  (n=223) 17 19 92.37% 91.47%
WNT (n=70) 12 11 82.85% 84.28%
Misassignment Accuracy
Subgroups Average-linkage Ward.D2 Average-linkage Ward.D2 
SHH (n=27) 4 4 85.18% 85.18%
WNT (n=24) 0 0 100% 100%
b
a
Cruzeiro et al. Acta Neuropathologica Communications            (2019) 7:33 Page 8 of 10
advantage of the qPCR method is that it does not require
batched minimal number of samples per run, being readily
available to run single tumor samples upon arrival at the
laboratory.
Conclusions
In conclusion, we have developed a simplified approach
and validated TDLA method in random samples by
Methylation Array 450 K. In addition, our findings were
challenged at a large cohort study GSE85217 through
accurate algorithms for molecular assignment of MB.
The proposed assay is cost-effective and discriminates
most of SHH, WNT, non-SHH/non-WNT tumors. The
TLDA method for MB subgroup stratification might be
an affordable tool to be used to drive therapies in
low-income countries. Moreover, it may also be an im-
portant approach for prompt classification and
decision-making algorithms in MB, before NGS data
analysis become available.
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